Recently Launched!
Check out Investor Copilot custom GPT, which lets you enjoy ChatGPT functionality with recent financial information
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
[ADAP] Adaptimmune Therapeutics plc - Other Non-Current Liabilities
Data updated 2024-Mar-23 (Saturday)Note: Detailed Statistics for Other Non-Current Liabilities in Balance Sheet for Adaptimmune Therapeutics plc [NASDAQ:ADAP] with frequency distribution chart that analyze trends & history . Other Non-Current Liabilities include Deferred Taxes, Provisions for Risks etc. View Balance Sheet for broader context
Share
Quarterly Other Non-Current Liabilities values for Adaptimmune Therapeutics plc are rounded to enhance readability
| 2023-Dec | 2023-Sep | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sep | |
|---|---|---|---|---|---|---|
| Other Non-Current Liabilities | 170 M | 113 M | 119 M | 121 M | 162 M | 133 M |
| Sequential Quarter Growth | +50.9% | -4.9% | -1.6% | -25.7% | +22.1% | -12.1% |
| Quarter-on Quarter Growth | +5.0% | -15.1% | -21.5% | -27.9% | -8.8% | +178.5% |
Annual Other Non-Current Liabilities values for Adaptimmune Therapeutics plc are rounded to enhance readability
| 2023-Dec | 2022-Dec | 2021-Dec | 2020-Dec | 2019-Dec | 2018-Dec | |
|---|---|---|---|---|---|---|
| Other Non-Current Liabilities | 170 M | 162 M | 178 M | 49.9 M | 598 K | 5.41 M |
| Year-on-Year Growth | +5.0% | -8.8% | +256.5% | +8,245.2% | -89.0% | +40.7% |
| 2-yr CAGR | -2.2% | +80.3% | +1,624.8% | +203.6% | -60.6% | -56.1% |
| 3-yr CAGR | +50.6% | +547.3% | +220.3% | +134.9% | -72.3% | |
| 4-yr CAGR | +310.8% | +134.0% | +160.7% | +15.4% | ||
| 5-yr CAGR | +99.3% | +111.3% | +44.6% |
Frequency distribution of quarterly Other Non-Current Liabilities values from 2015-Sep-30 grouped into buckets. Latest Other Non-Current Liabilities value is 170 Million as of 2023-Dec-31
Subsequent stock performance post earnings date till next announcement for Adaptimmune Therapeutics plc mapped with quarterly Other Non-Current Liabilities values reported at that time. Most recent value denoted with star
Select frequency and calculation type for Other Non-Current Liabilities above for vertical axis in scatter chart. Additionally choose type of performance for horizontal axis
Bayesian (Conditional Probability) analysis for Adaptimmune Therapeutics plc with subsequent post-earnings performance given Other Non-Current Liabilities values. Analysis uses quarterly data and subsequent relative performance benchmarked to S&P 500 index. Most recent quarter is denoted with a star and corresponding partial performance is excluded from calculations
| Underperform (relative perf.) | Outperform (relative perf.) | |
|---|---|---|
| Other Non-Current Liabilities - Low | 65% | 35% |
| Other Non-Current Liabilities - Medium | 47% | 53% |
| Other Non-Current Liabilities - High | 41% | 59% |
| Other Non-Current Liabilities (Sequential growth %) - Low | 47% | 53% |
| Other Non-Current Liabilities (Sequential growth %) - Medium | 61% | 39% |
| Other Non-Current Liabilities (Sequential growth %) - High | 41% | 59% |
| Other Non-Current Liabilities (QoQ growth %) - Low | 61% | 39% |
| Other Non-Current Liabilities (QoQ growth %) - Medium | 57% | 43% |
| Other Non-Current Liabilities (QoQ growth %) - High | 35% | 65% |
Related to Adaptimmune Therapeutics plc
Information for Adaptimmune Therapeutics plc
Current Detail : Recent daily/monthly performance & benchmark comparison
Historical Detail : Historical performance & related information using Time Machine
Financial Statements : Analyze Income Statement, Balance Sheet & Cashflow Statement and also compare with peers Currently Viewing
Bayesian Statement Classifier : Investigate historical financial statements to make probabalistic predictions using Artificial Intelligence
Anomaly Detection : Investigate unusual recent performance & technicals with historical context using AI
Historical Seasonality : Seasonal performance by calendar months
Technical History : Popular Technical indicator trends (RSI, MACD etc.)
Metric Deciles : Contextualizing recent performance & technical levels into historical decile buckets
Dollar Cost Averaging : Dollar Cost Average (DCA) over time in your portfolio
Moving Averages : Key Simple & Exponential Moving Averages
Historical Analogues : Insights from closest historical matches to recent performance using Artificial Intelligence
Chart Pattern Matching : Insights from similar historical charts to recent chart using Artificial Intelligence
News Stories : News stories on 2025-May-20 on Google
SEC Reports : Quarterly reports around 2025-May-20 on SEC Edgar
Compare Adaptimmune Therapeutics plc with other assets
Market Performance : Recent performance across covered assets
Historical Performance : Prior & Subsequent performance across assets on a historical date
Market Technicals : Technical indicator levels across covered assets
Market Seasonality : Seasonal performance by calendar months across covered assets
Pair Correlations : Performance Correlations with other assets
Beta : Volatility relative to the broad market
Performance Comparison : Visually compare/benchmark performance with other assets over time
Side-by-Side Comparison : Contrast with other assets over time in a side-by-side presentation
Sector : Health Care sector performance which includes Adaptimmune Therapeutics plc
Industry : Biotechnology industry performance which includes Adaptimmune Therapeutics plc